




OS subgroup analysis by BRCAm and HRD status



	Olaparib + bevacizumab (N=157)	Placebo + bevacizumab (N=80)
Events, n (%)	48 (30.6)	37 (46.3)
Median OS, months	75.2 (unstable)†	66.9
5-year OS rate, %	73.2	53.8
PARPi as subsequent treatment, n (%)	38 (24.2)	44 (55.0)
HR 0.60 (95% CI 0.39–0.93)		

	Olaparib + bevacizumab (N=97)	Placebo + bevacizumab (N=55)
Events, n (%)	44 (45.4)	32 (58.2)
Median OS, months	NR	52.0
5-year OS rate, %	54.7	44.2
PARPi as subsequent treatment, n (%)	9 (9.3)	23 (41.8)
HR 0.71 (95% CI 0.45–1.13)		

	Olaparib + bevacizumab (N=192)	Placebo + bevacizumab (N=85)
Events, n (%)	140 (72.9)	58 (68.2)
Median OS, months	36.8	40.4
5-year OS rate, %	25.7	32.3
PARPi as subsequent treatment, n (%)	46 (24.0)	34 (40.0)
HR 1.19 (95% CI 0.88–1.63)		

*By central labs; †Unstable median; <50% data maturity; ‡By Myriad myChoice HRD Plus. NR, not reported.